Pharmacokinetics of high-dose cytarabine and its deamination product-A reappraisal

被引:22
作者
Burk, M
Heyll, A
Arning, M
Volmer, M
Fartash, K
Schneider, W
机构
[1] Clin. Hematol., Oncol. Clin. I., Heinrich Heine University, Düsseldorf
关键词
cytarabine; pharmacokinetics; deamination; acute leukemia; individualization of therapy; uracil arabinoside;
D O I
10.3109/10428199709059686
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cytarabine is intracellularly activated and correlations have been established between the pharmacokinetic behaviour of active metabolites and their antileukemic effect. Recently, a good response to high-dose treatment of leukemias has additionally been attributed to a so-called low deamination phenotype of cytarabine inactivation. Consequently, these findings would support plasma level monitoring of cytarabine and its metabolite uracil arabinoside in high-dose cytarabine regimens. This pharmacokinetic study presents data attempting to reevaluate these observations. Thirty-seven patients were treated by 3-h high-dose cytarabine infusions (9 patients 1000 mg/m(2), 28 patients 3000 mg/m(2)) as part of their treatment for acute leukemia. Serial blood samples during and post infusion were analysed for cytarabine (araC) and its deamination product uracil arabinoside (araU) using HPLC with UV-detection. Considerable interindividual variation was observed in end-infusion plasma concentrations of araC (1000 mg/m(2): 2.1-fold, 3000 mg/m(2): 5.5-fold) and araU (1000 mg/m(2): 2.7-fold, 3000 mg/m(2): 2.9-fold). The median ratio of end infusion concentrations araU/araC (on a molar basis) was 5.6 (S.D. 3.0), extreme ratio values were 2 and 14. No differences of the araU/araC ratio were found between the two dosages used. Minimum plasma araC concentrations at the end of infusion were 10.5 mu mol/l and 22.0 mu mol/l at a dose of 1000 and 3000 mg/m(2), respectively. In our European study population a ''fast'' deamination phenotype of cytarabine (araU/araC ratio > 14) was not be observed.
引用
收藏
页码:321 / 327
页数:7
相关论文
共 25 条
  • [1] Allerheiligen S, 1994, P AN M AM SOC CLIN, V13, P136
  • [2] BURK M, 1995, ARZNEIMITTEL-FORSCH, V45-1, P616
  • [3] ALTERATION OF THE PHARMACOKINETICS OF HIGH-DOSE ARA-C BY ITS METABOLITE, HIGH ARA-U IN PATIENTS WITH ACUTE-LEUKEMIA
    CAPIZZI, RL
    YANG, JL
    CHENG, E
    BJORNSSON, T
    SAHASRABUDHE, D
    TAN, RS
    CHENG, YC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (12) : 763 - 771
  • [4] CHANDRASEKARAN B, 1989, CANCER RES, V49, P3259
  • [5] DEOXYPYRIMIDINE-INDUCED INHIBITION OF THE CYTOKINETIC EFFECTS OF 1-BETA-DEUTERIUM-ARABINOFURANOSYLURACIL
    CHANDRASEKARAN, B
    KUTE, TE
    CAPIZZI, RL
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 29 (06) : 455 - 460
  • [6] DAMON LE, 1991, CANCER RES, V51, P4141
  • [7] ESTEY E, 1987, LEUKEMIA, V1, P580
  • [8] FLEMING RA, 1995, CANCER CHEMOTH PHARM, V36, P425, DOI 10.1007/s002800050345
  • [9] Gibaldi M. P., 1982, PHARMACOKINETICS
  • [10] Heinzel G, 1993, TOPFIT 2 0 PHARMACOK